ASCO Gastrointestinal Cancers Symposium | Conferences

brPROPHET May Better Detect ctDNA and Identify MRD in Colorectal Cancer

January 23, 2023

According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.

ctDNA Serves as Biomarker for Early Response Assessment in Advanced CRC

January 23, 2023

Compared with other tumor biomarkers, circulating tumor DNA may be ideal for early response assessment and have potential to enable use of adaptive clinical study designs in the future for patients with advanced colorectal cancer.

Adding Veliparib or Pembrolizumab to Neoadjuvant Chemoradiation Not Beneficial for Locally Advanced Rectal Cancer

January 21, 2023

NRG-GI002 helps to provide further total neoadjuvant therapy outcome data from multi-institutional national clinical trials that can benchmark and be used for future locally advanced rectal cancer outcomes, according to Thomas J. George, MD, FACP.

Sorafenib in Combination with SBRT Extends Survival in Locally Advanced HCC

January 21, 2023

The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.